A new drug, Donanemab (Kusement), developed by Eli Lilly, has been approved by the FDA to treat patients with early Alzheimer’s disease and mild cognitive impairment. However, it’s not suitable for every patient due to potential side effects and risks, resulting in many patients being turned away. The drug significantly slows down the progression of the disease, but it does not reverse memory loss or cognitive function.
Click here for more information…
New Alzheimer’s Drug Offers Hope, But Limited Availability
